Introducing and Bioinformatic Evaluation of a Chimeric and Effective Immunogen Construct for Designing a Recombinant Vaccine against Brucellosis.

Nazifi, Narges

doi:10.22034/jahid.2024.710979

Introducing and Bioinformatic Evaluation of a Chimeric and Effective Immunogen Construct for Designing a Recombinant Vaccine against Brucellosis.

Document Type : Original Article

Author

Narges Nazifi

Department of Basic Sciences, Faculty of Veterinary Medicine, Lorestan University, Khorramabad, Iran

10.22034/jahid.2024.710979

Abstract

Background and Aim: Malt fever is a zoonotic disease caused by Brucellosis bacteria (an obligate intracellular pathogen) which is highly contagious. Usually, in common vaccines to deal with this pathogen, the whole body of the bacteria is used. Therefore, it causes many side effects. Nowadays, the use of subunit vaccines with the aim of eliminating pathogenic parts and strengthening immunogenic parts has been highly regarded.
Materials and Methods: In this study, the epitopes of L7/L12, BLS and bp26 antigens of Brucella bacteria were used to design the recombinant immunogenic structure. For this purpose, the reliable and online IEDB and IFNepitope servers were used to predict the epitopes of each antigens. After identifying the strongest epitopes of these antigens, structural engineering was performed using epitopes, peptide linkers and HBHA as a molecular adjuvant. Evaluation of the physicochemical properties, secondary structure, tertiary structure, antigenicity and allergenicity of the protein sequence of the recombinant construct were performed by ProtParam, SOPMA, I-TASSER, VaxiJen and AllerTOP servers, respectively. Finally, after predicting the second and third structure of the recombinant structure by SOPMA and I-TASSER servers, the protein-protein interaction between the HBHA molecule present in the recombinant structure and the TLR4/MD-2 receptor was investigated using ClusPro online server.
Results: Based on the results, the recombinant structure was successfully designed in two adjuvant (N-terminal) and epitopic (C-terminal) domains using rigid EAAAK linker. Other evaluations showed that the recombinant structure with a molecular weight of 36256.13 Da and an isoelectric point of 8.37, has an aliphatic index of 77.10 and a GRAVY index of -0.613. Also, based on this instability index, this protein is classifiedas a stable protein. Further investigations revealedthat this structure was reported to be a non-allergenic structure with an antigenicity score of 0/8287. The results of protein-protein docking showed that the interaction between HBHA molecule and TLR4/MD-2 receptor with 62 cluster members and the lowest binding energy of -858.8 kcal/mol will be done successfully.
Conclusion: Therefore, the epitope-based recombinant structure can be introduced as a successful structure for engineering subunit vaccines.

Keywords

Bioinformatics

Subunit Vaccine

Brucellosis

Recombinant Protein

Epitope

HBHA

1. Vizcaino N, Cloeckaert A, Zygmunt MS, Dubray G. Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein. Infection and immunity. 1996;64(9):3744-51.

2. Moreno E, Cloeckaert A, Moriyón I. Brucella evolution and taxonomy. Veterinary microbiology. 2002;90(1-4):209-27.

3. Corbel M. Recent advances in brucellosis. Journal of medical microbiology. 1997;46(2):101-3.

4. Jaydari A, Nazifi N, Forouharmehr A. Computational design ofa novel multi-epitope vaccine against Coxiella burnetii. Human Immunology. 2020;81(10-11):596-605.

5. Delany I, Rappuoli R, Seib KL. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harbor perspectives in medicine. 2013;3(5).

6. Tahamtan A, Charostad J, Shokouh SJH, Barati M. An overview of history, evolution, and manufacturing of various generations of vaccines. Journal of Archives in Military Medicine. 2017;5(3).

7. Jorge S, Dellagostin OA. The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches. Biotechnology Research and Innovation. 2017;1(1):6-13.

8. Bachrach G, Banai M, Fishman Y, Bercovier H. Delayed-type hypersensitivity activity of the Brucella L7/L12 ribosomal protein depends on posttranslational modification. Infection and immunity. 1997;65(1):267-71.

9. Perkins SD, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans. FEMS microbiology reviews. 2010;34(3):379-94.

10. Kazak E, Costa Oliveria S, Goral G, Akalin H, Yilmaz E, Heper Y, et al. Brucella abortus L7/L12 recombinant protein induces strong Th1 response in acute brucellosis patients. Iranian journal of immunology. 2010;7(3):132-41.

11. Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infection and immunity. 2005;73(12):8079-88.

12. Velikovsky CA, Goldbaum FA, Cassataro J, Estein S, Bowden RA, Bruno L, et al. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infection and immunity. 2003;71(10):5750-5.

13. Chen X, Zaro JL, Shen W-C. Fusion protein linkers: property, design and functionality. Advanced drug delivery reviews. 2013;65(10):1357-69.

14. Nazifi N, Tahmoorespur M, Sekhavati MH, Haghparast A, Behroozikhah MA. Assessment of signal peptides to optimize interleukin 2 (IL-2) folding and expression. Current Proteomics. 2019;16(3):188-98.

15. Forouharmehr A, Nassiri M, Ghovvati S, Javadmanesh A. Evaluation of different signal peptides for secretory production of recombinant bovine pancreatic ribonuclease A in gram negative bacterial system: an in silico study. Current Proteomics. 2018;15(1):24-33.

1. Luirink J, Sinning I. SRP-mediated protein targeting: structure and function revisited. Biochim Biophys Acta. 2004;1694.

17. Sobolev BN, Olenina LV, Kolesanova EF, Poroikov VV, Archakov AI. Computer design of vaccines: approaches, software tools and informational resources. Current Computer-Aided Drug Design. 2005;1(2):207-22.

18. Rappuoli R. Reverse vaccinology. Current opinion in microbiology. 2000;3(5):445-50.

19. Tomar N, De RK. Immunoinformatics: an integrated scenario. Immunology. 2010;131(2):153-68.

20. Korber B, LaBute M, Yusim K. Immunoinformatics comes of age. PLoS Computational Biology. 2006;2(6):e71.

21. Van Regenmortel M, editor Synthetic peptides versus natural antigens in immunoassays. Annales de biologie clinique; 1993.

22. Tahmoorespur M, Nazifi N, Pirkhezranian Z. In silico prediction of B-cell and T-cell epitopes of protectiveantigen of Bacillus anthracis in development of vaccines against anthrax. Iranian Journal of Applied Animal Science. 2017;7(3):429-36.

23. Forouharmehr A, Nazifi N, Mousavi SM, Jaydari A. Designing an efficient epitope-based vaccine conjugated with a molecular adjuvant against Bovine Babesiosis: A computational study. Process Biochemistry. 2022;121:170-7.

24. Nazifi N, Mousavi SM, Moradi S, Jaydari A, Jahandar MH, Forouharmehr A. In Silico B Cell and T Cell epitopes evaluation of lipL32 and OmpL1 proteins for designing a recombinant multi-epitope vaccine against leptospirosis. International Journal of Infection. 2018;5: (2).

25. Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino acids. 2006;30:351-67.

26. Aguilar J, Rodriguez E. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752-62.

27. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature medicine. 2007;13(5):552-9.

28. Jung ID, Jeong SK, Lee C-M, Noh KT, Heo DR, Shin YK, et al. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Research. 2011;71(8):2858-70.

29. Rashidian E, Gandabeh ZS, Forouharmehr A, Nazifi N, Shams N, Jaydari A. Immunoinformatics approach to engineer a potent poly-epitope fusion protein vaccine against Coxiella burnetii. International Journal of Peptide Research and Therapeutics. 2020;26:2191-201.

30. Shams N, Forouharmehr A. Assembling the Most Antigenic Peptides of COVID-19 Immunogenic Proteins Along with a Molecular Adjuvant to Develop a Novel Polyepitope Vaccine: a Bioinformatics Investigation. Vaccine Research. 2021;8(1):36-46.

31. Rashidian E, Forouharmehr A, Nazifi N, Jaydari A, Shams N. Computer-aided design of a novel poly-epitope protein in fusion with an adjuvant as a vaccine candidate against leptospirosis. Current Proteomics. 2021;18(2):113-23.

32. Shams N, Shakarami Gandabeh Z, Nazifi N, Forouharmehr A, Jaydari A, Rashidian E. Computational design of different epitope-based vaccines against Salmonella typhi. International Journal of Peptide Research and Therapeutics. 2020;26:1527-39.

33. Walker JM. The proteomics protocols handbook: Springer; 2005.

34. Ikai A. Thermostability and aliphatic index of globular proteins. The Journal of Biochemistry. 1980;88(6):1895-8.

35. Enany S. Structural and functional analysis of hypothetical and conserved proteins of Clostridium tetani. Journal of infection and public health. 2014;7(4):296-307.

36. Zhang J, Tao A. Antigenicity, immunogenicity, allergenicity. Allergy bioinformatics. 2015:175-86.